Remnant cholesterol and ischemic heart disease

Current Opinion in Lipidology

Volumn 25, Issue 4, 2014, Pages 266-273

  Varbo, Anette ^a,b   Nordestgaard, Børge G ^a,b  

^a Mental Health Center Glostrup   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

atherosclerosis; cardiovascular disease; cholesterol; lipoprotein; remnants

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTERY WALL; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; GENETIC ASSOCIATION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPID STORAGE; LIVER CLEARANCE; MENDELIAN RANDOMIZATION ANALYSIS; PRIORITY JOURNAL; REVIEW;

EID: 84904185198     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000093     Document Type: Review

References (57)

1. Shaikh M, Wootton R, Nordestgaard BG, et al. Quantitative studies of transfer in vivo of low density, Sf 12-60 and Sf 60-400 lipoproteins between plasma and arterial intima in humans. Arterioscler Thromb 1991; 11:569-577.
2. Nordestgaard BG, Tybjærg-Hansen A, Lewis B. Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants. Arterioscler Thromb 1992; 12:6-18.
3. Nordestgaard BG, Wootton R, Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb Vasc Biol 1995; 15:534-542.
4. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991; 11:2-14.
5. Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298:309-316.
6. Nordestgaard BG, Benn M, Schnohr P, Tybjærg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298:299-308.
7. Freiberg JJ, Tybjærg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008; 300:2142-2152.
8. Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302:1993-2000.
9. Langsted A, Freiberg JJ, Tybjærg-Hansen A, et al. Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: The Copenhagen City Heart Study with 31 years of follow-up. J Intern Med 2011; 270:65-75.
10. Varbo A, Nordestgaard BG, Tybjærg-Hansen A, et al. Nonfasting triglycerides, cholesterol, and ischemic stroke in the general population. Ann Neurol 2011; 69:628-634.
11. Varbo A, Benn M, Nordestgaard BG. Remnant cholesterol as a cause of ischemic heart disease: Evidence, definition, measurement, atherogenicity, high-risk patients, and present and future treatment. Pharmacol Ther 2014; 141:358-367.
12. Varbo A, Benn M, Tybjærg-Hansen A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013; 61:427-436.
13. Jørgensen AB, Frikke-Schmidt R, West AS, et al. Genetically elevated nonfasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J 2013; 34:1826-1833.
14. Varbo A, Benn M, Tybjærg-Hansen A, Nordestgaard BG. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation 2013; 128:1298-1309.
15. Kasahara A, Adachi H, Hirai Y, et al. High level of plasma remnant-like particle cholesterol may predispose to development of hypertension in normotensive subjects. Am J Hypertens 2013; 26:793-798.
16. Shiina Y, Homma Y. Relationships between the visceral fat area on CT and coronary risk factor markers. Intern Med 2013; 52:1775-1780.
17. Slyper AH, Rosenberg H, Kabra A, et al. Early atherogenesis and visceral fat in obese adolescents. Int J Obes (Lond) 2014. [Epub ahead of print]. doi:10.1038/ijo.2014.11.
18. Hegele RA, Ginsberg HN, Chapman MJ, et al. The polygenic nature of hypertriglyceridaemia: Implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2013. [Epub ahead of print]. doi:10.1016/S2213- 8587(13)70191-8.
19. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010; 466:707-713.
20. Deloukas P, Kanoni S, Willenborg C, et al. Large-scale association analysis identifies newrisk loci for coronary artery disease. Nat Genet 2013; 45:25-33.
21. Peloso GM, Auer PL, Bis JC, et al. Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. Am J Hum Genet 2014; 94:223-232.
22. Lawlor DA, Harbord RM, Sterne JA, et al. Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology. Stat Med 2008; 27:1133-1163.
23. Thomsen M, Varbo A, Tybjærg-Hansen A, Nordestgaard BG. Low nonfasting triglycerides and reduced all-cause mortality: A Mendelian randomization study. Clin Chem 2014; 60:737-746. doi:10.1373/clinchem.2013. 219881.
24. Do R, Willer CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet 2013; 45:1345-1352.
25. Jorde R, Grimnes G. Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids. Prog Lipid Res 2011; 50:303-312.
26. Gofman JW, Hanig M, Jones JB, Lauffer MA, et al. Evaluation of serum lipoprotein and cholesterol measurements as predictors of clinical complications of atherosclerosis; report of a cooperative study of lipoproteins and atherosclerosis. Circulation 1956; 14:691-742.
27. Ramasamy I. Recent advances in physiological lipoprotein metabolism. Clin Chem Lab Med 2013. [Epub ahead of print]. doi: 10.1515/cclm-2013-0358.
28. Foley EM, Gordts PL, Stanford KI, et al. Hepatic remnant lipoprotein clearance by heparan sulfate proteoglycans and low-density lipoprotein receptors depend on dietary conditions in mice. Arterioscler Thromb Vasc Biol 2013; 33:2065-2074.
29. Matikainen N, Burza MA, Romeo S, et al. Genetic variation in SULF2 is associated with postprandial clearance of triglyceride-rich remnant particles and triglyceride levels in healthy subjects. PLoS One 2013; 8:e79473.
30. Frazier-Wood AC, Kabagambe EK, Wojczynski MK, et al. The association between LRP-1 variants and chylomicron uptake after a high fat meal. Nutr Metab Cardiovasc Dis 2013; 23:1154-1158.
31. Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: Evidence and guidance for management. Eur Heart J 2011; 32:1345-1361.
32. Gotto AM Jr, Moon JE. Recent clinical studies of the effects of lipid-modifying therapies. Am J Cardiol 2012; 110:15A-26A.
33. Kakuda H, Kobayashi J, Nakato M, Takekoshi N. Short-term effect of pitavastatin treatment on glucose and lipid metabolism and oxidative stress in fasting and postprandial state using a test meal in Japanese men. Cholesterol 2013; 2013:314170.
34. Mangili OC, Moron Gagliardi AC, Mangili LC, et al. Favorable effects of ezetimibe alone or in association with simvastatin on the removal from plasma of chylomicrons in coronary heart disease subjects. Atherosclerosis 2014; 233:319-325.
35. Tsunoda T, Nozue T, Yamada M, et al. Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance. Diabetes Res Clin Pract 2013; 100:46-52.
36. Torimoto K, Okada Y, Mori H, et al. Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes. Lipids Health Dis 2013; 12:137.
37. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223:405-418.
38. Canner PL, Berge KG, Wenger NK, et al. Fifteen-year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J Am Coll Cardiol 1986; 8:1245-1255.
39. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365:2255-2267.
40. Rizos EC, Ntzani EE, Bika E, et al. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: A systematic review and meta-analysis. JAMA 2012; 308:1024-1033.
41. Casula M, Soranna D, Catapano AL, Corrao G. Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized, double blind, placebo controlled trials. Atheroscler Suppl 2013; 14:243-251.
42. Kastelein JJ, Maki KC, Susekov A, et al. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. J Clin Lipidol 2014; 8:94-106.
43. Brinton EA, Ballantyne CM, Bays HE, et al. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: The ANCHOR study. Cardiovasc Diabetol 2013; 12:100.
44. Gotto AM Jr, Moon JE. Pharmacotherapies for lipid modification: Beyond the statins. Nat Rev Cardiol 2013; 10:560-570.
45. Graham MJ, Lee RG, Bell TA III, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res 2013; 112:1479-1490.
46. Lee P, Hegele RA. Current phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia. Expert Opin Investig Drugs 2013; 22:1411-1423.
47. Cuchel M, Meagher EA, du Toit TH, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: A single-arm, open-label, phase 3 study. Lancet 2013; 381:40-46.
48. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebo-controlled trial. Lancet 2010; 375:998-1006.
49. Annuzzi G, Bozzetto L, Costabile G, et al. Diets naturally rich in polyphenols improve fasting and postprandial dyslipidemia and reduce oxidative stress: A randomized controlled trial. Am J Clin Nutr 2014; 99:463-471.
50. Dash S, Xiao C, Morgantini C, et al. High-dose resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men. Arterioscler Thromb Vasc Biol 2013; 33:2895-2901.
51. Xiao C, Dash S, Morgantini C, Lewis GF. New and emerging regulators of intestinal lipoprotein secretion. Atherosclerosis 2014; 233:608-615.
52. Gylling H, Plat J, Turley S, et al. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis 2014; 232:346-360.
53. Kim HJ, Moon JH, Kim HM, et al. The hypolipidemic effect of cilostazol can be mediated by regulation of hepatic low-density lipoprotein receptor-related protein 1 (LRP1) expression. Metabolism 2014; 63:112-119.
54. Grosskopf I, Shaish A, Ray A, et al. Low molecular weight heparin-induced increase in chylomicron-remnants clearance, is associated with decreased plasma TNF-alpha level and increased hepatic lipase activity. Thromb Res 2014; 133:688-692.
55. Matikainen N, Taskinen MR. The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with type 2 diabetes. Diabet Med 2013; 30:756-757.
56. Noda Y,Miyoshi T, Oe H, et al. Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in nondiabetic subjects: A preliminary report. Cardiovasc Diabetol 2013; 12:8.
57. Xiao C, Dash S, Morgantini C, et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans. Diabetes 2014. [Epub ahead of print]. doi:10.2337/db13-1654.